Pooled weighted responder proportion for all treatments reported in at least one other study with five or more participants
| Treatment | Entity | Responders | Total | Pooled weighted responder proportion (95% CI) | Heterogeneity (I2) |
| Preventative treatments | |||||
| Lamotrigine | SUNHA | 118 | 216 | 0.56 (0.49 to 0.63) | 49% |
| SUNCT | 80 | 137 | 0.59 (0.50 to 0.68) | 47% | |
| SUNA | 38 | 76 | 0.50 (0.38 to 0.62) | 64% | |
| Carbamazepine | SUNHA | 43 | 158 | 0.26 (0.19 to 0.34) | 0% |
| SUNCT | 23 | 87 | 0.26 (0.17 to 0.36) | 80% | |
| SUNA | 19 | 63 | 0.30 (0.19 to 0.42) | 25% | |
| Gabapentin | SUNHA | 35 | 143 | 0.22 (0.15 to 0.30) | 93% |
| SUNCT | 24 | 87 | 0.26 (0.17 to 0.36) | 94% | |
| SUNA | 10 | 48 | 0.19 (0.02 to 0.32) | 81% | |
| Topiramate | SUNHA | 34 | 121 | 0.27 (0.19 to 0.36) | 28% |
| SUNCT | 29 | 75 | 0.39 (0.28 to 0.50) | 35% | |
| SUNA | 4 | 40 | 0.09 (0.01 to 0.21) | 0% | |
| Pregabalin | SUNHA | 9 | 89 | 0.10 (0.04 to 0.17) | 0% |
| SUNCT | 5 | 44 | 0.10 (0.02 to 0.22) | 0% | |
| SUNA | 4 | 45 | 0.09 (0.02 to 0.19) | 0% | |
| Oxcarbazepine | SUNHA | 30 | 76 | 0.38 (0.27 to 0.50) | 87% |
| SUNCT | 14 | 36 | 0.38 (0.22 to 0.56) | 51% | |
| SUNA | 16 | 40 | 0.37 (0.22 to 0.54) | 86% | |
| Transitional treatments | |||||
| Parenteral lidocaine | SUNHA | 89 | 96 | 0.94 (0.88 to 0.98) | 9% |
| SUNCT | 58 | 62 | 0.95 (0.87 to 1.00) | 0% | |
| SUNA | 31 | 35 | 0.91 (0.77 to 1.00) | 0% | |
| Greater occipital nerve blockade | SUNHA | 30 | 94 | 0.31 (0.22 to 0.41) | 79% |
| SUNCT | 17 | 59 | 0.28 (0.17 to 0.41) | 66% | |
| SUNA | 13 | 35 | 0.36 (0.19 to 0.54) | 58% | |
SUNA, short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT, short-lasting unilateral neuralgiform attacks with conjunctival injection and tearing; SUNHA, short-lasting unilateral neuralgiform headache attacks.